Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir-Reference-Cited by-同舟云学术

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

Published:2014-01-12 Issue:6 Volume:15 Page:330-338
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Martinez E¹,Gonzalez-Cordon A¹,Ferrer E²,Domingo P³,Negredo E⁴,Gutierrez F⁵,Portilla J⁶,Curran A⁷,Podzamczer D²,Murillas J⁸,Bernardino JI⁹,Santos I¹⁰,Carton JA¹¹,Peraire J¹²,Pich J¹,Perez I¹,Gatell JM¹,

Affiliation:

1. Hospital Clínic-IDIBAPS; Universitat de Barcelona; Barcelona Spain

2. Hospital Universitari de Bellvitge; Universitat de Barcelona; L'Hospitalet de Llobregat Spain

3. Hospital de Sant Pau; Universitat Autònoma de Barcelona; Barcelona Spain

4. Lluita contra la SIDA Foundation; Hospital Germans Trías i Pujol; Universitat Autònoma de Barcelona; Badalona Spain

5. Hospital Universitario de Elche; Universidad Miguel Hernández; Elche Spain

6. Hospital Universitario de Alicante; Universidad de Alicante; Alicante Spain

7. Hospital Universitari Vall d'Hebron; Universitat Autònoma de Barcelona; Barcelona Spain

8. Hospital Son Espases; Palma de Mallorca Spain

9. Hospital Univrsitario La Paz; Universidad Autónoma de Madrid; Madrid Spain

10. Hospital Universitario de La Princesa; Universidad Autónoma de Madrid; Madrid Spain

11. Hospital Universitario Central de Asturias; Universidad de Oviedo; Oviedo Spain

12. Hospital Universitari Joan XXIII, Universitat Rovira i Virgili; Tarragona Spain

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Reference26 articles.

1. Panel de expertos de Gesida y Plan Nacional sobre el Sida Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2013) http://www.gesida-seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2013-TAR-adulto.pdf 2013

2. European AIDS Clinical Society (EACS) Guidelines (Version 6.1 - November 2012 http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6.1-2edition.pdf

3. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the international antiviral society-USA panel;Thompson;JAMA,2012

4. Principles and practice of HIV-protease inhibitor pharmacoenhancement;Moyle;HIV Med,2001

5. Once-daily ATV/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study;Molina;Lancet,2008

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impacts of ainuovirine-based and efavirenz-based antiretroviral therapies on the lipid profile of HIV/AIDS patients in southern China: a real-world study;Frontiers in Medicine;2024-01-08

2. Coronary heart disease in patients with human immunodeficiency virus infection;Medical Journal of the Russian Federation;2023-02-23

3. Management of hypercholesterolemia in individuals living with HIV/AIDS;Cholesterol;2022

4. Cardiovascular risks associated with protease inhibitors for the treatment of HIV;Expert Opinion on Drug Safety;2021-07-26

5. Association Between Atazanavir‐Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV;Journal of the American Heart Association;2020-10-06